Document ID: chunk:federal_register_of_legislation:C2010A00126:clause:6_33
Version: federal_register_of_legislation:C2010A00126
Segment Type: clause
Provision Reference: sch 6 cl 33
Character Range: 60801–62437

33  Transitional provisions relating to PBAC advice or recommendations given before commencement
(1) If, before commencement, the Minister had obtained the advice of the Pharmaceutical Benefits Advisory Committee under subsection 85(2AB) of the main Act in relation to a proposed revocation or variation under subsection 85(2AA) of that Act, then, on and after commencement, that advice is to be treated (and may be dealt with) as if:
 (a) it had been obtained under subsection 101(4AAB) of that Act; and
 (b) it related to a proposed revocation or variation under subsection 101(4AAA) of that Act.
(2) If, before commencement, the Pharmaceutical Benefits Advisory Committee had recommended under paragraph 100AA(4)(a) of the main Act that the Minister make a declaration in relation to a drug or medicinal preparation under subsection 100AA(2) of that Act, then, on and after commencement, that recommendation is to be treated (and may be dealt with) as if:
 (a) it had been obtained under subsections 101(4) and (4AAD) of that Act; and
 (b) it related to declarations under subsections 85(2) and (2A) of that Act.
(3) If, before commencement, the Minister had obtained the advice of the Pharmaceutical Benefits Advisory Committee under subsection 100AA(5) of the main Act in relation to the revocation or variation of a declaration under subsection 100AA(2) of that Act, then, on and after commencement, that advice is to be treated (and may be dealt with) as if:
 (a) it had been obtained under subsection 101(4AAB) of that Act; and
 (b) it related to a revocation or variation of a declaration under subsection 85(2) of that Act.